LAUSANNE, Switzerland and BANGALORE, India, November 20 Debiopharm Group (Debiopharm), a global biopharmaceutical developmentspecialist that focuses on serious medical conditions and particularlyoncology, and Aurigene Discovery Technologies Ltd (Aurigene), aBangalore-based fully integrated, global biotech focused on small moleculeand peptide drug discovery and development from target identification andvalidation to pre-IND drug candidates, signed an exclusive worldwide licenseagreement, excluding the territories of Japan and the rest of Asia, todevelop and commercialise Debio 0617, a novel inhibitor of an undisclosedoncology pathway. Utilising its know-how and fragment-based drug deliverytechnology platform, Aurigene has generated potent leads against the target.Under the terms of the agreement, Debiopharm will pay Aurigene an upfrontfee, as well as further payments according to predefined discovery,development and sales milestones.
"We are very excited to continue our collaboration with Aurigene. Theirbusiness model offers a one stop solution for structure guided drug design,lead optimization and preclinical work. The Debio 0617 project aims atdeveloping inhibitors targeting a key oncology pathway, which plays essentialroles in various solid tumors and haematological malignancies," saidRolland-Yves Mauvernay, President & Founder of Debiopharm Group.
"Partnering with Debiopharm, a highly focused and successful drugdevelopment company, is highly synergistic for Aurigene, a drug discoverybiotech. Aurigene has been collaborating with Debiopharm on two otherprograms for three years now, and the current licensing agreement withDebiopharm serves to reiterate the high quality of science and competence atAurigene. This further strengthens the relationship between the companies,"added CSN Murthy, CEO of Aurigene.
About Debiopharm Group
Debiopharm Group is a global biopharmaceutical development specialistthat in-licenses promising biologics and small molecule drug candidates. Itdevelops its products for global registration and maximum commercialpotential for out-licensing to pharmaceutical partners for sales andmarketing.
Debiopharm independently funds the worldwide development of all of itsproducts while providing expertise in pre-clinical and clinical trials,manufacturing, drug delivery and formulation, and regulatory affairs.
Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharmhas developed three products with global combined sales in excess of $2.65billion in 2007.
For more information on Debiopharm Group, please visit:http://www.debiopharm.com.
Established in Bangalore, India, in 2002, Aurigene Discovery TechnologiesLtd., is a drug discovery biotech focused on small molecule and peptide drugdiscovery and development from target identification and validation topre-IND drug candidates in oncology, metabolic disorders and autoimmunediseases, with a proven track record of successful partnerships with big andmedium-sized pharma and biotech companies globally. Aurigene has 10 drugdiscovery collaborations and a pipeline of 15 discovery programs at variousstages, from Hit Generation to late-stage Pre-Clinical Optimization, and hasfiled 14 patents across 6 programs over the last 12 months.
With proprietary Structural Biology and Fragment-based Drug Designtechnology platforms, and experienced scientific leadership, Aurigene is afully integrated operation with expertise in Hit Generation to DrugDevelopment Candidates for IND nomination.Debiopharm S.A. Contacts Maurice Wagner Director Corporate Affairs & Communications Tel.: +41(0)21-321-01-11 Fax: +41(0)21-321-01-69 firstname.lastname@example.org Additional Media Contacts In London Maitland Brian Hudspith Tel: +44(0)20-7379-5151 email@example.com Jo-Anne Lutjens Communications Manager Tel.: +41(0)79-370-27-15 Fax: +41(0)21-321-01-69 firstname.lastname@example.org In New York Russo Partners, LLC Wendy Lau Tel: +1-212-845-4272 Fax: +1-212-845-4260 email@example.com Aurigene Contacts Sonita Chada Manager, Corporate Communications Tel: +91-80-2852-1314 Sonita_c@aurigene.com
SOURCE The Debiopharm Group